Limitations of antifungal agents in the treatment of Candida vaginitis: Future challenges

Drug Resistance Updates

Volumn 2, Issue 3, 1999, Pages 148-152

  Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NON PRESCRIPTION DRUG; NYSTATIN; TERCONAZOLE; TIOCONAZOLE;

CANDIDA ALBICANS; CANDIDA GLABRATA; DRUG EFFICACY; DRUG POTENCY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; INTRAVAGINAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT INFECTION; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; VAGINA CANDIDIASIS;

EID: 0033150122     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0088     Document Type: Article

References (25)

1. Berg A. O., Heidrich R. D., Fihn S. D. Establishing the cause of symptoms in women in a family practice. J Am Med Aassoc. 251:1984;620-625.
2. Geiger A. M., Foxman B., Gillespie B. W. Epidemiology of vulvovaginal candidiasis among university students. Am J Public Health. 85:1995;1146-1148.
3. Geiger A. M., Foxman B. Risk factors in vulvovaginal candidiasis: a case-control study among college students. Epidemiol. 1996;182-187.
4. Hurley R., DeLouvois J. Candida vaginitis. Postgrad Med J. 55:1979;645-647.
5. Odds F. C., odd R. C. (ed). Candidiasis of the genitalia. Candida and candidosis. A review and bibliography, 2nd edition. 1988;Balliere Tindal, London. p. 124-135.
6. Horowitz B. J., Giaquinta D., Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 32:1992;248-255.
7. Foxman B. Epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health. 80:1990;329-331.
8. Ferris D. G., Dekle C., Litaker M. S. Women's use of over-the-counter antifungal pharmaceutical products for gynecologic symptoms. J Fam Pract. 42:1996;595-600.
9. Reef, S. Levine, W. C. McNeil, M. M. Treatment options for vulvovaginal candidiasis. Background paper for development of 1993 STD treatment recommendations. Clin Infect Dis 1995; 20 (Suppl): 580-590.
10. Sobel J. D., Brooker D., Stein G. E. Single oral dose fluconazole compared with conventional topical therapy of Candida vaginitis. Am J Obstet Gynecol. 172:1995;1263-1268.
11. Sobel J. D., Faro S., Force R. W., Foxman B. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol. 178:1998;203-211.
12. Houang E. T., Byrne D., Macrae P. V., Thoiper J. E. Fluconazole levels in plasma and vaginal secretions of patients with the 150 mg single dose and rate of eradication of infections in vaginal candidiasis. Antimicrob Agents Chemother. 34:1990;909-913.
13. Sobel J. D. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 152:1985;924-934.
14. Vazquez J. A., Sobel J. D., Demitriou R., Vaishampayan J., Lynch M., Zervos M. J. Karyotyping of C. albicans. 170:1994;1566-1569.
15. Carrata L., Pizzoli G. Recurrent vulvovaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir. J Reproduct Med. 37:1992;343-347.
16. Fidel P. J. Jr, Sobel J. D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev. 9:1996;335-348.
17. Chaim W., Foxman B., Sobel J. D. Association of recurrent vaginal candidiasis and secretory ABO+ Lewis phenotype. J Infect Dis. 176:1997;828-830.
18. Sobel J. D., Chaim W. Vaginal microbiology of women with recurrent vulvovaginal candidiasis. J Clin Micro. 34:1996;2397-2502.
19. Lewis J. H., Zimmerman H. J., Benson G. D. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology. 22:1984;503-513.
20. Spinillo A., Carratta L., Pizzoli G. Recurrent vaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir. J Reproduct Med. 37:1992;343-347.
21. Schuman P., Sobel J. D., Ohmit S. E., Mayer K. H. Mucosal candidal colonization and candidiasis in women with or at risk for HIV infection. Clin Infect Dis. 27:1998;1161-1167.
22. Vazquez J. A., Sobel J. D., Peng G., Steele-Moore L. Evolution of vaginal Candida species recovered from HIV-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata ? Clin Infect Dis. 28:1999;1025-1031.
23. Sobel J. D. Vulvovaginitis due to Candida glabrata vaginitis: an emerging problem. Mycoses. 41 (Suppl 2):1998;18-22.
24. Sobel J. D., Chaim W. Treatment of Candida glabrata vaginitis: A retrospective review of boric acid therapy. Clin Infect Dis. 24:1997;649-652.
25. Sobel J. D., Vazquez J. A. Symptomatic vulvovaginitis due to resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 22:1996;726-727.